11β-Hydroxysteroid dehydrogenase activity in acromegalic patients with normal or impaired carbohydrate metabolism

Steroids

Volumn 74, Issue 9, 2009, Pages 725-729

  Mondok, Agnes ^a   Varga, Ibolya ^a   Glaz, Edit ^a   Szucs, Nikolette ^a   Tóth, Miklós ^a   Patocs, Attila ^a   Beko, Gabriella ^a   Racz, Karoly ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

11 hydroxysteroid dehydrogenase; Acromegaly; Cortisol; Cortisone; Type 2 diabetes

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE; BROMOCRIPTINE; CARBOHYDRATE; CORTISONE; DESMOPRESSIN; GLUCOSE; HYDROCORTISONE; SEX HORMONE; SOMATOSTATIN DERIVATIVE; THYROXINE; 11BETA HYDROXYSTEROID DEHYDROGENASE 1;

ACROMEGALY; ADULT; AGED; ARTICLE; BLOOD SAMPLING; CARBOHYDRATE METABOLISM; COMPARATIVE STUDY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORTICOTROPIN DEFICIENCY; DIABETES INSIPIDUS; DISEASE ACTIVITY; ENZYME ACTIVITY; FEMALE; GLUCOSE TOLERANCE; HOMEOSTASIS; HUMAN; HYPOGONADISM; HYPOPHYSIS; HYPOTHYROIDISM; IRRADIATION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; SURGICAL TECHNIQUE; BLOOD; ENZYMOLOGY; GLUCOSE INTOLERANCE; METABOLISM; MIDDLE AGED; TIME;

11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1; ACROMEGALY; ADULT; AGED; AGED, 80 AND OVER; CARBOHYDRATE METABOLISM; CORTISONE; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCOSE INTOLERANCE; HUMANS; HYDROCORTISONE; MALE; MIDDLE AGED; TIME FACTORS;

EID: 67349100180     PISSN: 0039128X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.steroids.2009.03.003     Document Type: Article

References (36)

1. Stewart P.M. 11β-hydroxysteroid dehydrogenase: implications for clinical medicine. Clin Endocrinol (Oxf) 44 (1996) 493-499
2. Tannin G.M., Agarwal A.K., Monder C., New M.I., and White P.C. The human gene for 11β-hydroxysteroid dehydrogenase. Structure, tissue distribution, and chromosomal localization. J Biol Chem 266 (1991) 16653-16658
3. Moore J.S., Monson J.P., Kaltsas G., Putignano P., Wood P.J., Sheppard M.C., et al. Modulation of 11β-hydroxysteroid dehydrogenase isoenzymes by growth hormone and insulin-like growth factor: in vivo and in vitro studies. J Clin Endocrinol Metab 84 (1999) 4172-4177
4. Stewart P.M. Tissue specific Cushing's syndrome, 11β-hydroxysteroid dehydrogenases and the redefinition of corticosteroid hormone action. Eur J Endocrinol 149 (2003) 163-168
5. Fruchter O., Zoumakis E., Alesci S., deMartino M., Chrousos G., and Hochberg Z. Intracrine modulation of gene expression by intracellular generation of active glucocorticoids. Steroids 71 (2006) 1001-1006
6. Bujalska I.J., Walker E.A., Hewison M., and Stewart P.M. A switch in dehydrogenase to reductase activity of 11beta-hydroxysteroid dehydrogenase type 1 upon differentiation of human omental adipose stromal cells. J Clin Endocrinol Metab 87 (2002) 1205-1210
7. Tomlinson J.W., Walker E.A., Bujalska I.J., Draper N., Lavery G.G., Cooper M.S., et al. 11β-hydroxysteroid dehydrogenase type-1: a tissue-specific regulator of glucocorticoid response. Endocr Rev 25 (2004) 831-866
8. Stewart P.M., Toogood A.A., and Tomlinson J.W. Growth hormone, insulin-like growth factor-I and the cortisol-cortisone shuttle. Horm Res 56 Suppl. 1 (2001) 1-6
9. Funder J.W., Pearce P.T., Smith R., and Smith A.I. Mineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated. Science 242 (1988) 583-585
10. Albiston A.L., Obeyesekere V.R., Smith R.E., and Krozowski Z.S. Cloning and tissue distribution of the human 11β-hydroxysteroid dehydrogenase type 2 enzyme. Mol Cell Endocrinol 105 (1994) 11-17
11. Edwards C.R.W., Benedictsson R., Lindsay R.S., and Seckl J.R. 11β-hydroxysteroid dehydrogenases: key enzymes in determining tissue-specific glucocorticoid effects. Steroids 61 (1996) 263-269
12. Stulnig T.M., and Waldhäusl W. 11β-hydroxysteroid dehydrogenase type 1 in obesity and type 2 diabetes. Diabetologia 47 (2004) 1-11
13. Dötsch J., Dörr H.G., Stalla G.K., and Sippell W.G. Effect of glucocorticoid excess on the cortisol/cortisone ratio. Steroids 66 (2001) 817-820
14. Sandeep T.C., and Walker B.R. Pathophysiology of modulation of local glucocorticoid levels by 11β-hydroxysteroid dehydrogenases. Trends Endocrinol Metab 12 (2001) 446-453
15. Walker E.A., and Stewart P.M. 11β-hydroxysteroid dehydrogenase: unexpected connections. Trends Endocrinol Metab 14 (2003) 334-339
16. Seckl J.R., and Walker B.R. 11β-hydroxysteroid dehydrogenase type 1 as a modulator of glucocorticoid action: from metabolism to memory. Trends Endocrinol Metab 15 (2004) 418-424
17. Gelding S.V., Taylor N.F., Wood P.J., Noonan K., Weaver J.U., Wood D.F., et al. The effect of growth hormone replacement therapy on cortisol-cortisone interconversion in hypopituitary adults: evidence for growth hormone modulation of extrarenal 11β-hydroxysteroid dehydrogenase activity. Clin Endocrinol 48 (1998) 153-162
18. Toogood A.A., Taylor N.F., Shalet N.P., and Monson J.P. Modulation of cortisol metabolism by low-dose growth hormone replacement in elderly hypopituitary patients. J Clin Endocrinol Metab 85 (2000) 1727-1730
19. Beentjes J.A.M., Kerstens M.N., and Dullaart R.P.F. Effects of growth hormone replacement on cortisol metabolism in hypopituitary patients treated with cortisone acetate. Scand J Clin Lab Invest 61 (2001) 277-286
20. Giavoli C., Libé R., Corbetta S., Ferrante E., Lania A., Arosio M., et al. Effect of recombinant human growth hormone (GH) replacement on the hypothalamic-pituitary-adrenal axis in adult GH-deficient patients. J Clin Endocrinol Metab 89 (2004) 5397-5401
21. Paulsen S.K., Pedersen S.B., Jorgensen J.O.L., Fisker S., Christiansen J.S., Flyvbjerg A., et al. Growth hormone (GH) substitution in GH-deficient patients inhibits 11β-hydroxysteroid dehydrogenase type 1 messenger ribonucleic acid expression in adipose tissue. J Clin Endocrinol Metab 91 (2006) 1093-1098
22. Agha A., and Monson J.P. Modulation of glucocorticoid metabolism by the growth hormone-IGF1 axis. Clin Endocrinol 66 (2007) 459-465
23. Trainer P.J., Drake W.M., Perry L.A., Tavlor N.F., Besser G.M., and Monson J.P. Modulation of cortisol metabolism by the growth hormone receptor antagonist pegvisomant in patients with acromegaly. J Clin Endocrinol Metab 86 (2001) 2989-2992
24. Frajese G.V., Taylor N.F., Jenkins P.J., Besser G.M., and Monson J.P. Modulation of cortisol metabolism during treatment of acromegaly is independent of body composition and insulin sensitivity. Horm Res 61 (2004) 246-251
25. Vierhapper H., Nowotny P., and Waldhausl W. Urinary steroid excretion rates in acromegaly. Horm Res 63 (2005) 234-237
26. Gong R., Morris D.J., and Brem A.S. Human renal 11β-hydroxysteroid dehydrogenase 1 functions and co-localizes with COX-2. Life Sci 82 (2008) 631-637
27. Stewart P.M. Commentary: 'The fat lady sings', but what is she telling us?. Clin Endocrinol 48 (1988) 9-10
28. Walker B.R., Connacher A.A., Lindsay R.M., Webb D.J., and Edwards C.R. Carbenoxolone increases hepatic insulin sensitivity in man: a novel role for 11-oxosteroid reductase in enhancing glucocorticoid receptor activation. J Clin Endocrinol Metab 80 (1995) 3155-3159
29. Andrews R.C., Rooyackers O., and Walker B.R. Effects of the 11β-hydroxysteroid dehydrogenase inhibitor carbenoxolone on insulin sensitivity in men with type 2 diabetes. J Clin Endocrinol Metab 88 (2003) 285-291
30. Masuzaki H., Paterson J., Shinyama H., Morton N.M., Mullins J.J., Seckl J.R., et al. A transgenic model of visceral obesity and the metabolic syndrome. Science 294 (2001) 2166-2170
31. Kannisto K., Pietilainen K.H., Ehrenborg E., Rissanen A., Kaprio J., Hamsten A., et al. Overexpression of 11β-hydroxysteroid dehydrogenase-1 in adipose tissue is associated with acquired obesity and features of insulin resistance: studies in young adult monozygotic twins. J Clin Endocrinol Metab 89 (2004) 4414-4421
32. Valsamakis G., Anwar A., Tomlinson J.W., Shackleton C.H.L., McTernan P.G., Chetty R., et al. 11β-hydroxysteroid dehydrogenase type-1 activity in lean and obese males with type 2 diabetes mellitus. J Clin Endocrinol Metab 89 (2004) 4755-4761
33. Morton N.M., Paterson J.M., Masuzaki H., Holmes M.C., Staels B., Fiever C., et al. Novel adipose tissue-mediated resistance to diet-induced visceral obesity in 11β-hydroxysteroid dehydrogenase type 1-deficient mice. Diabetes 53 (2004) 931-938
34. Fotsch C., and Wang M. Blockade of glucocorticoid excess at the tissue level: inhibitors of 11β-hydroxysteroid dehydrogenase type 1 as a therapy for type 2 diabetes. J Med Chem 51 (2008) 4851-4857
35. Berger J., Tnen M., Elbrecht A., Hermanowski-Vosatka A., Moller D.E., Wright S.D., et al. Peroxisome proliferator-activated receptor-gamma ligands inhibit adipocyte 11β-hydroxysteroid dehydrogenase type 1 expression and activity. J Biol Chem 276 (2001) 12629-12635
36. Pfutzner A., Kunt T., Hohberg C., Mondok A., Pahler S., Konrad T., et al. Fasting intact proinsulin is a highly specific marker of insulin resistance in type 2 diabetes. Diab Care 27 (2004) 682-687